Physician profile
Keith A Johnson
NPI 1902829583
$3,878.47
in general payments reported to CMS, 2019-2025
30 companies · $901 in 2025
The $901 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $612 · 2022: $110 · 2023: $1,090 · 2024: $1,165 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,155 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.34 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $562.18 | 2021-2025 | |
| Novo Nordisk INC | $367.69 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $268.43 | 2021-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $259.96 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $205.84 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.50 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Astellas Pharma US INC | $195.46 | 2021-2025 | Veozah, Myrbetriq |
| Philips North America LLC | $187.61 | 2021-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Amgen INC. | $184.21 | 2021-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $167.96 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $149.40 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $142.59 | 2023-2024 | Accrufer |
| Ibsa Pharma INC. | $133.17 | 2023-2025 | Tirosint, Licart, Flector |
| Janssen Pharmaceuticals, INC | $107.38 | 2021-2024 | Xarelto |
| Abbott Laboratories | $82.51 | 2023-2024 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $78.36 | 2023-2025 | Gemtesa |
| Dexcom, INC. | $76.82 | 2024-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $74.62 | 2024-2025 | Cequr Simplicity |
| Grifols USA, LLC | $69.01 | 2025 | Prolastin-C Liquid |
| Baxter Healthcare | $46.47 | 2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Argenx US, INC. | $43.27 | 2025 | Vyvgart Hytrulo |
| Verona Pharma, INC. | $42.47 | 2025 | Ohtuvayre |
| Esperion Therapeutics, INC. | $39.99 | 2024-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $39.89 | 2021 | |
| Vifor Pharma, INC. | $34.04 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $32.30 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $31.51 | 2021-2023 | Seglentis |
| Daiichi Sankyo INC. | $24.57 | 2023 | Enhertu |
| Biogen, INC. | $16.58 | 2021 | |
| Genentech USA, INC. | $15.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.